Published March 4, 2022
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses osimertinib (Tagrisso), 40 mg and 80 mg tablets, orally.
- Indication: As adjuvant therapy after tumour resection in patients with stage IB to stage IIIA non–small cell lung cancer whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.